# High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

> **NCT02551718** · NA · COMPLETED · sponsor: **University of Washington** · enrollment: 34 (actual)

## Conditions studied

- Recurrent Acute Leukemia of Ambiguous Lineage
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Acute Leukemia of Ambiguous Lineage

## Interventions

- **OTHER:** Chemosensitivity Assay
- **OTHER:** Cytology Specimen Collection Procedure
- **GENETIC:** Gene Expression Analysis
- **GENETIC:** Genetic Variation Analysis
- **DRUG:** In Vitro Sensitivity-Directed Chemotherapy

## Key facts

- **NCT ID:** NCT02551718
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2020-06-19
- **Final completion:** 2021-05-13
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551718, "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02551718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*